Bone marrow hypoplasia in a cat treated with griseofulvin.
Three weeks after initiation of griseofulvin treatment for dermatophytosis (40 mg/kg of body weight, q 12 h), an 8-yr-old domestic shorthair cat developed depression, vomiting, and pyrexia. Abnormalities found during physical examination included bilateral mydriasis, visual impairment, grade-II/V systolic murmur and multiple areas of alopecia. The cat was pancytopenic; serum biochemical abnormalities included hyperbilirubinemia, hyperglycemia, hyponatremia, and hypokalemia, and urinalysis revealed proteinuria, glycosuria, and bilirubinuria. Examination of a bone marrow aspirate revealed profound hypoplasia of all precursors. Griseofulvin toxicosis was diagnosed on the basis of the temporal relationship of drug administration with onset of clinical, hematologic, and biochemical abnormalities and failure to identify an infective or neoplastic cause for the bone marrow hypoplasia. The condition was refractory to treatment and the cat was euthanatized. Pathologic changes in the bone marrow were consistent with severe hypoplasia of all bone marrow precursors.
Rottman
J B
JB
Department of Companion Animal, College of Veterinary Medicine, North Carolina State University, Raleigh 27606.
English
R V
RV
Breitschwerdt
E B
EB
Duncan
D E
DE
D000818:Animals; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000662:veterinary*; D002371:Cat Diseases / Q000139:chemically induced*; D002415:Cats; D003937:Diagnosis, Differential; D005260:Female; D006118:Griseofulvin / Q000009:adverse effects*; D010198:Pancytopenia / Q000139:chemically induced / Q000662:veterinary*
D006118:Griseofulvin